Angioedema Induced by Ace Inhibitors (AEACEI)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema Induced by Ace Inhibitors

MalaCards integrated aliases for Angioedema Induced by Ace Inhibitors:

Name: Angioedema Induced by Ace Inhibitors 57 72
Angioedema Induced by Ace Inhibitors, Susceptibility to 57 29 6 39
Acquired Angioedema 58 70
Aeacei 57 72
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioneurotic Edema 58
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioedema 58
Drug-Related Side Effects and Adverse Reactions 44
Acquired Angioedema with Normal C1 Inhibitor 58
Acquired Non Histamine-Induced Angioedema 58
Ace Inhibitor-Related Acquired Angioedema 58
Raas-Blocker-Induced Angioneurotic Edema 58
Acquired Bradykinine-Induced Angioedema 58
Acquired Angioedema with Normal C1inh 58
Acquired C1 Inhibitor Deficiency 58
Acei-Related Acquired Angioedema 58
Raas-Blocker-Induced Angioedema 58
Acquired Angioneurotic Edema 58
Ae-Acei 72
Rae 58
Aae 58


Orphanet epidemiological data:

acquired angioedema
Inheritance: Not applicable; Age of onset: Adult;
renin-angiotensin-aldosterone system-blocker-induced angioedema
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;


Orphanet: 58  
Rare systemic and rhumatological diseases
Rare allergic disease

External Ids:

OMIM® 57 300909
MESH via Orphanet 45 C538173
ICD10 via Orphanet 33 T78.3
UMLS via Orphanet 71 C2931758
SNOMED-CT via HPO 68 400075008 41291007
UMLS 70 C2931758

Summaries for Angioedema Induced by Ace Inhibitors

OMIM® : 57 Approximately 40 million people take ACE inhibitors (ACEi) to treat hypertension and cardiovascular disease. A small proportion of white patients who take ACEi (0.1-0.7%) develop angioedema (AEACEI) (Israili and Hall, 1992; Vleeming et al., 1998), a potentially life-threatening side effect characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe. ACEi-associated angioedema is 4 to 5 times more prevalent among African Americans (Brown et al., 1996; Coats, 2002). Other risk factors include female sex, smoking, immunosuppressant therapy, and seasonal allergies. The pathophysiology of ACEi-associated angioedema is thought to be related to increased circulating bradykinin, which is normally degraded by ACE. During pharmacologic ACE inhibition, bradykinin is primarily degraded by aminopeptidase P (summary by Duan et al., 2005 and Woodard-Grice et al., 2010). Aminopeptidase P is encoded by 3 genes: XPNPEP1 (602443) on chromosome 10q25, XPNPEP2 (300145) on chromosome Xq25, and XPNPEP3 (613553) on chromosome 22q13. (300909) (Updated 05-Apr-2021)

MalaCards based summary : Angioedema Induced by Ace Inhibitors, also known as angioedema induced by ace inhibitors, susceptibility to, is related to acquired angioedema and angioedema, hereditary, type i. An important gene associated with Angioedema Induced by Ace Inhibitors is XPNPEP2 (X-Prolyl Aminopeptidase 2). The drugs Phenylephrine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, skin and bone, and related phenotypes are angioedema and Decreased hepcidin::fluc mRNA expression

UniProtKB/Swiss-Prot : 72 Angioedema induced by ACE inhibitors: A potentially life-threatening side effect of ACE inhibitors that appears in a subset of patients taking these drugs for hypertension and cardiovascular disease treatment. AEACEI is characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe.

Related Diseases for Angioedema Induced by Ace Inhibitors

Diseases related to Angioedema Induced by Ace Inhibitors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 acquired angioedema 11.6
2 angioedema, hereditary, type i 11.4
3 acquired angioedema type 1 11.1
4 acquired angioedema type 2 11.1
5 acquired angioedema with c1inh deficiency 11.1
6 reactive angioendotheliomatosis 11.0
7 complement component 4, partial deficiency of 10.6
8 c1 inhibitor deficiency 10.6
9 hereditary angioedema 10.6
10 angioedema 10.5
11 lymphoproliferative syndrome 10.3
12 urticaria 10.2
13 sjogren syndrome 10.2
14 cryoglobulinemia 10.2
15 marginal zone b-cell lymphoma 10.2
16 leukemia, chronic lymphocytic 10.1
17 splenic marginal zone lymphoma 10.1
18 lymphoma 10.1
19 leukemia 10.1
20 vitiligo-associated multiple autoimmune disease susceptibility 6 10.1
21 vitiligo-associated multiple autoimmune disease susceptibility 1 10.1
22 graves' disease 10.1
23 food allergy 10.1
24 complement deficiency 10.1
25 cryoglobulinemia, familial mixed 10.0
26 melkersson-rosenthal syndrome 10.0
27 mantle cell lymphoma 10.0
28 nephrotic syndrome 10.0
29 facial paralysis 10.0
30 echinococcosis 10.0
31 monoclonal paraproteinemia 10.0
32 macroglobulinemia 10.0
33 amyloidosis 10.0
34 al amyloidosis 10.0
35 lymphosarcoma 10.0
36 splenomegaly 10.0
37 marfan syndrome 10.0
38 cardiac arrest 10.0
39 aortic valve insufficiency 10.0
40 autoimmune disease 10.0
41 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
42 chronic urticaria 10.0
43 allergic disease 10.0
44 thrombophilia 10.0
45 antiphospholipid syndrome 10.0
46 monoclonal gammopathy of uncertain significance 10.0
47 multiple sclerosis 9.9
48 esophageal cancer 9.9
49 human immunodeficiency virus type 1 9.9
50 primary biliary cholangitis 9.9

Graphical network of the top 20 diseases related to Angioedema Induced by Ace Inhibitors:

Diseases related to Angioedema Induced by Ace Inhibitors

Symptoms & Phenotypes for Angioedema Induced by Ace Inhibitors

Human phenotypes related to Angioedema Induced by Ace Inhibitors:

# Description HPO Frequency HPO Source Accession
1 angioedema 31 HP:0100665

Clinical features from OMIM®:

300909 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Angioedema Induced by Ace Inhibitors according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased hepcidin::fluc mRNA expression GR00253-A 8.62 G6PD XPNPEP2

Drugs & Therapeutics for Angioedema Induced by Ace Inhibitors

Drugs for Angioedema Induced by Ace Inhibitors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 531)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Phenylephrine Approved Phase 4 59-42-7 6041
Ephedrine Approved Phase 4 299-42-3 9294
Pseudoephedrine Approved Phase 4 90-82-4 7028
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Cyclopentolate Approved Phase 4 512-15-2 2905
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Eprosartan Approved Phase 4 133040-01-4 5281037
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Trandolapril Approved Phase 4 87679-37-6 5484727
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Ramipril Approved Phase 4 87333-19-5 5362129
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
Zofenopril Approved Phase 4 81872-10-8
Enalaprilat Approved Phase 4 76420-72-9 6917719
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Losartan Approved Phase 4 114798-26-4 3961
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Fosinopril Approved Phase 4 98048-97-6 55891
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Ribavirin Approved Phase 4 36791-04-5 37542
Etomidate Approved Phase 4 33125-97-2 36339 667484
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
Meclizine Approved Phase 4 569-65-3 4034
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Thrombin Approved, Investigational Phase 4
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
BCG vaccine Approved, Investigational Phase 4

Interventional clinical trials:

(show top 50) (show all 315)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of MR and APDT Vaccine Unknown status NCT01830257 Phase 4
2 Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study Unknown status NCT03368391 Phase 4 tetracaine HCl and oxymetazoline HCL;2% Lidocaine with 1:100,000 epinephrine;3% Mepivacaine with 1:100,000 epinephrine;saline intranasal;saline infiltration
3 Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status NCT00173901 Phase 4 ceftazidime
4 Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. Unknown status NCT03638726 Phase 4 Atropine sulfate and epinephrine;Topical cyclopentolate and phenylephrine
5 Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics? - A Pilot Study. Optional Deoxyribo-Nucleic Acid Donation for the Study of Hypertension. Unknown status NCT01715584 Phase 4
6 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
7 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
8 The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting Unknown status NCT02213718 Phase 4 Desflurane;propofol;sufentanil
9 Motion Sickness Medications and Vestibular Time Constant Unknown status NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
10 Evaluation of CYP4A11 and CYP4F2 Gene Variants as Makers in Edema and Elevated Blood Pressure Occurrence After Nonsteroidal Anti-inflammatory (NSAID) Use Completed NCT02779530 Phase 4 Diclofenac
11 Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers Completed NCT01775839 Phase 4 Aspirin+Clopidogrel/Digoxin(oral);Aspirin+Clopidogrel/Digoxin(IV)
12 An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection Completed NCT02811185 Phase 4 [F-18]-Fludeoxyglucose
13 Title of Study: Adverse Drug Event (ADE) Incidence in Older Patients Following Hospital Admission and Pharmacist Review to Older Persons' Prescriptions and Its' Effect on ADE Reduction in Hospital: a Randomised Controlled Trial Completed NCT01467128 Phase 4
14 Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Using STOPP/START Criteria Completed NCT01467050 Phase 4
15 Safety and Immunogenicity of Adjuvanted Versus High-Dose Inactivated Influenza Vaccines in Older Adults Completed NCT03183908 Phase 4
16 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Completed NCT02864030 Phase 4 ERIBULIN MESYLATE
17 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4
18 A Phase IV Open Label Study of the Effects of a Five Minute Infusion Time for Ethyol (Amifostine) in Patients Undergoing Chemotherapy Completed NCT00003252 Phase 4 amifostine trihydrate
19 A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen Completed NCT01679964 Phase 4 Raltegravir switch
20 Aminotransferase Trends During Prolonged Therapeutic Acetaminophen Dosing Completed NCT00743093 Phase 4 acetaminophen;placebo
21 Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC Recruiting NCT04701151 Phase 4 Bacillus Calmette Guerin
22 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
23 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
24 Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV Recruiting NCT04340388 Phase 4 Dolutegravir 50 MG;Antiretroviral/Anti HIV
25 The Study of Potential Normalization of Cardiac Rhythm Following Drug Exchange From Chimeric Methadone to Active Methadone Active, not recruiting NCT04254731 Phase 4 Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)
26 Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. A Randomized Placebo-controlled Trial Not yet recruiting NCT04671589 Phase 4 Meropenem Injection
27 Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy Terminated NCT02296840 Phase 4 Ibuprofen;Hydrocodone-Acetaminophen
28 Optimal Method of Pain Control After Minimally Invasive Coronary Artery Bypass Grafting Terminated NCT01770236 Phase 4 IV acetaminophen
29 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Terminated NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
30 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
31 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
32 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
33 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
34 An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
35 Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer Completed NCT01080547 Phase 3 XELOX Chemotherapy;mFolfox6 chemotherapy
36 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
37 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
38 A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3 Completed NCT00324298 Phase 3 cisplatin;etoposide
39 A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome Completed NCT00296036 Phase 3 urea/lactic acid-based topical cream
40 A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin Completed NCT00003313 Phase 3 amifostine trihydrate;carboplatin;paclitaxel
41 Improving Safety by Basic Computerizing Outpatient Prescribing Completed NCT01091038 Phase 2, Phase 3
42 A Phase III Investigation Of Topical Application Of RX0041-002 On Safety And Efficacy In Local (Topical) Anesthesia For Diagnostic Procedures And Surgeries On Or Through The Accessible Mucous Membranes Of The Nasal Cavities Completed NCT02667054 Phase 3 RX0041 4%;Placebo;RX0041 8%
43 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
44 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
45 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
46 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
47 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
48 Phase I/II Trial of Amifostine, High-Dose Cisplatin and Docetaxel in Patients With Advanced Lung Cancer Unknown status NCT00004264 Phase 1, Phase 2 amifostine trihydrate;cisplatin;docetaxel
49 A Phase II Trial Using Amifostine as a Chemo/Radio Protective Agent in the Treatment of Limited Stage Small-Cell Lung Cancer Unknown status NCT00003583 Phase 2 amifostine trihydrate;cisplatin;etoposide
50 Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride

Search NIH Clinical Center for Angioedema Induced by Ace Inhibitors

Cochrane evidence based reviews: drug-related side effects and adverse reactions

Genetic Tests for Angioedema Induced by Ace Inhibitors

Genetic tests related to Angioedema Induced by Ace Inhibitors:

# Genetic test Affiliating Genes
1 Angioedema Induced by Ace Inhibitors, Susceptibility to 29 XPNPEP2

Anatomical Context for Angioedema Induced by Ace Inhibitors

MalaCards organs/tissues related to Angioedema Induced by Ace Inhibitors:

Tongue, Skin, Bone, Brain, Liver, Myeloid, Spinal Cord

Publications for Angioedema Induced by Ace Inhibitors

Articles related to Angioedema Induced by Ace Inhibitors:

(show all 15)
# Title Authors PMID Year
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. 57 6
21898657 2011
Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. 6 57
20625347 2010
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. 6 57
16175507 2005
Omapatrilat--the story of Overture and Octave. 57
12243845 2002
Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. 57
12086766 2002
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 57
10458510 1999
ACE inhibitor-induced angioedema. Incidence, prevention and management. 57
9530537 1998
Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. 57
8689816 1996
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. 57
1616218 1992
Tranexamic acid adverse reactions: a brief summary for internists and emergency doctors. 61
32908455 2020
[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors]. 61
29735174 2018
Angioedema. 61
28818177 2017
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? 61
20163043 2009
[Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases]. 61
10198947 1999
[Behçet's disease and angioedema induced by ACE-inhibitors: 2 unusual pathological pictures]. 61
9409950 1997

Variations for Angioedema Induced by Ace Inhibitors

ClinVar genetic disease variations for Angioedema Induced by Ace Inhibitors:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 XPNPEP2 NG_011479.1:g.2846C>A SNV risk factor 11567 rs3788853 GRCh37: X:128870791-128870791
GRCh38: X:129736814-129736814
2 G6PD NM_000402.4(G6PD):c.653C>T (p.Ser218Phe) SNV Uncertain significance 100057 rs5030868 GRCh37: X:153762634-153762634
GRCh38: X:154534419-154534419

Expression for Angioedema Induced by Ace Inhibitors

Search GEO for disease gene expression data for Angioedema Induced by Ace Inhibitors.

Pathways for Angioedema Induced by Ace Inhibitors

GO Terms for Angioedema Induced by Ace Inhibitors

Cellular components related to Angioedema Induced by Ace Inhibitors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 8.62 XPNPEP2 G6PD

Sources for Angioedema Induced by Ace Inhibitors

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....